Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-term extension study (data cut-off: August 2017; database not locked, data may change).
Eligible patients from two phase (P) 3 (P3) tofacitinib PsA studies (OPAL Broaden, NCT01877668; O...
- Publication status:
- Peer review status:
- Peer reviewed
- Copyright holder:
- Nash et al.
- Rights statement:
- © The Author(s) 2020. This article is published under an open access license.
- CC Attribution (CC BY)
Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study
If you are the owner of this record, you can report an update to it here: Report update to this record